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INTRODUCTION
During World War I,  many soldiers who
sustained thoracic and non-thoracic injuries
developed diffuse lung infiltrates, respiratory
failure, which progressed into non-cardiogenic
pulmonary oedema, severe hypoxaemia and
majority of the patients died. Sometimes
pancreatitis, massive blood transfusion, sepsis
and other conditions also may be the causative
factors for respiratory distress syndrome (RDS).
Ashbaugh et al1 described 12 such patients in
1967, and used the term “adult respiratory
distress syndrome” to describe this condition
because there existed another entity called
“infant respiratory distress syndrome (IRDS)’’.
Subsequently,  a  committee  of  leading
investigators in the field met in 1994 to develop
a consensus between the American Thoracic
Society (ATS) and the European Society of
Intensive Care Medicine (ESICM). The AECC
changed the term from “adult respiratory
distress syndrome” to “acute respiratory distress
syndrome (ARDS)’’ because the syndrome
occurrd in both adults and children.2
The AECC2 defined ARDS as acute onset of
respiratory symptoms, bilateral infiltrates on the
frontal chest radiograph, pulmonary capillary
wedge pressure (PCWP) less than 18 mm Hg
when measured or no evidence of left atrial
hypertension, ratio of arterial, oxygen: tension
(PaO2) to fraction of inspired oxygen (FIO2) less
than 200.
The AECC definition2 was widely adopted by
clinical researchers and clinicians and has
advanced the knowledge of ARDS by allowing
the acquisition of clinical and epidemiological
data. However, after 18 years of applied
research, a number of issues regarding various
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criteria of the AECC definition have emerged,
including a lack of explicit criteria for defining
acute, sensitivity of PaO2/FIO2 to different
ventilator settings, poor reliability of the chest
radiograph  criteria,  and  difficulties
distinguishing hydrostatic oedema. This led to
the genesis of Berlin definition.3
EPIDEMIOLOGY
The  incidence  of  ARDS  varies  widely.
Estimates from prospective US cohort studies
using the AECC definition2 range from 64.24
to 78.95 cases/100,000 person-years. Other
estimates were as follows: Northern Europe (17
cases/100,000),6 Spain (7.2 cases/100,000),7
and  Australia/New  Zealand  (34  cases/
100,000).8 Reasons for the large variation in
ARDS incidence are unclear, and may include
major  differences  in  demographics  and
healthcare delivery systems.7
The known causes and risk factors for the
development of ARDS (Table 1),9-11 can be
categorized as insults ensuing from either direct
or indirect injury to the lung. It is now well
established that sepsis is currently the most
commonly identified cause of ARDS, and is
associated with the worst outcome overall.5,11,12
Trauma-related ARDS has been typically
associated with significantly lower mortality
than other causes of ARDS.5
ARDS in the tropics
Rare, but important treatable causes of ARDS
in the tropics include infections, such as,
malaria,  tuberculosis,  enteric  fever,
leptospirosis, scrub  typhus, heart stroke,
paraquat poisoning, among others.
Malaria is an important treatable cause of
ARDS in the tropics including India and in the
returning traveler in the non-endemic areas.
ARDS is an important complication in severe,
complicated falciparum malaria and has been
described  in  Plasmodium  vivax  and
Plasmodium ovale malaria also.13,14 Malarial
ARDS is more common in adults than in
children. Pregnant women and non-immune
individuals are more prone to develop this
condition.  Increased  alveolar  capillary
permeability resulting in intravascular fluid loss
into  the  lungs  appears  to  be  the  key
pathophysiologic mechanism. In  malaria,
ARDS can develop either at initial presentation
or after initiation of treatment when the
parasitaemia is falling and the patient  is
improving.13
Mortality
Approximately 25% to 40% of ARDS cases are
fatal, which is an improvement from the ARDS,
mortality rate of 50% to 70% 20 years ago.16-18
Death usually results from multisystem organ
failure rather than respiratory failure alone.
According to Berlin definition3 increasing
severity  of ARDS  was  associated  with
increasing mortality (27%, 32%, and 45%).
PATHOGENESIS
Aspiration, trauma or sepsis can lead to the
insult or injury to the alveolar epithelium and
Table 1: Risk factors of ARDS
   Direct injury Indirect injury
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Common causes
Severe trauma with shock
and multiple transfusions
Sepsis
Uncommon causes
Cardiopulmonary bypass
Acute pancreatitis
Drug overdose
Transfusion of blood and
blood products
Common causes
Aspiration of  gastric
contents
Pneumonia
Uncommon causes
Fat embolism
Pulmonary contusion
Near-drowning
Inhalation injury
Reperfusion injury  after
lung  transplantation  or
embolectomy
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capillary endothelium. Injury is generally
detected  in  both  the  endothelium  and
epithelium at the time of diagnosis.19,20 This
injury invariably leads to a leakage of plasma
proteins through the interstitial compartment
and into the alveolar space. Many of these
plasma proteins in turn activate procoagulant
and proinflammatory pathways that lead to the
fibrinous and purulent exudates. There is
increased  release  of  proinflammatory
cytokines, and a profound acute inflammatory
response is generated. This is heralded by
epithelial cell apoptosis and necrosis,21 further
activation of other inflammatory cascades, and
a robust recruitment of neutrophils.22 The
release of various growth and profibrotic factors
can  ultimately  lead  to  healing  and/or
remodelling. The increased expression of tissue
facor and other procoagulant factors ultimately
leads  to  coagulation  within  the  micro-
vasculature and airspaces, accompanied by a
suppression of fibrinolysis that helps perpetuate
the microthrombi and fibrinous exudates that
are pathognomonic of ARDS.
Injury to the alveolar epithelium plays a critical
role in the pathogenesis of ARDS. The loss of
tight junctions and barrier function leads to
seepage of plasma proteins and oedema fluid
into the alveolar space, leading to increased
shunt fraction, higher alveolar surface tension,
and a greater propensity for alveolar collapse.
The resorption of protein from the alveolar
space is believed to occur more slowly, and is
differentially regulated depending on the
burden of protein present. Removal of larger
insoluble proteins, such as fibrin-rich hyaline
membranes requires degradation, and can take
much longer.23
The damaged and injured endothelium is also
play an important role in the pathogenesis of
ARDS  through  increased  endothelial
permeability,  release  of  inflammatory
molecules,  expression  of  cell  adhesion
molecules,  and  an  up-regulation  of
procoagulant pathways. Endothelial cells can
be  stimulated to  release preformed  von
Willebrand factor (vWF)24 as well as potent
neutrophil (PMN) activating factors.25
Endothelial activation in ARDS is highlighted
by the finding that elevated plasma vWF levels
have been shown to predict the development
of ARDS in patients at risk26 and predict poorer
outcomes in patients in whom ARDS has
already developed. Higher vWF levels are also
associated with fewer organ failure-free days
in patients with ARDS.27 Activated leucocytes
and endothelial cells can also contribute to
another recognized pathologic manifestation of
ARDS, namely dysregulated intravascular and
extravascular fibrin accumulation.28,29 Impaired
fibrinolysis and increased procoagulant activity
within the alveolar lining fluid have long been
recognized in patients with ARDS. Numerous
additional pathways have been implicated in
the  pathogenesis  of  ARDS,  Endotoxin
(lipopolysaccharide) is considered to be the
initiator of ARDS in the settings of sepsis and
pneumonia.30 Oxidant-mediated injury through
the generation of oxidant species such as
superoxide and hydrogen peroxide, is also a
well-recognized pathway for injury in ARDS.
Dysregulation of cell death and apoptosis
through the release and accumulation of soluble
Fas ligand is also thought to contribute to injury
and may also become a potential future target
for therapeutic intervention.21,31 The role of
mechanical ventilation in contributing to the
development and exacerbation of ARDS is now
widely recognized, its mechanisms extensively
researched,32,33 and its appreciation has led to
the most significant contribution to date in the
management of this condition: the use of lower
tidal volumes.
Inflammatory response leading to  organ
dysfunction and failure continues to be the
major problem after injury in many clinical
conditions such as sepsis, severe burns, acute
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pancreatitis, hemorrhagic shock, and trauma.
In general terms, systemic  inflammatory
response syndrome (SIRS) is an entirely normal
response  to  injury.  Systemic  leucocyte
activation, however, is a direct consequence of
a SIRS and if excessive, can lead to distant
organ damage and multiple organ dysfunction
syndrome (MODS). When SIRS leads to
MODS  and organ  failure, the  mortality
becomes high and can be more than 50%. Acute
lung injury that clinically manifests as ARDS
is a major component of MODS of various
etiologies. Inflammatory mediators play a key
role in the pathogenesis of ARDS, which is the
primary cause of death in these conditions.
Recent studies that demonstrate the critical role
played by inflammatory mediators such as
tumour  necrosis  factor  alpha  (TNF-),
interleukin (IL)-1beta, interleukin-6 (IL-6),
platelet activating factor (PAF), interleukin-10
(IL-10), granulocyte macrophage-colony
stimulating factor (GM-CSF), C5a, intercellular
adhesion molecule (ICAM)-1, substance P,
chemokines, vascular endothelial growth factor
(VEGF), insulin like growth factor-I (IGF-I),
keratinocyte growth factor (KGF), reactive
oxygen species (ROS), and reactive nitrogen
species (RNS) in the pathogenesis of ARDS.34
These  mechanisms  are  summarized  in
(Figure1)
PATHOPHYSIOLOGY
Due to accumulation of extravascular lung
water  (i.e.,  pulmonary  oedema),  the
physiological  derangements  of  ARDS
invariably manifest as refractory hypoxaemia,35
decreased respiratory compliance,2 and a
propensity for alveolar closure.36
As  alveolar  oedema  fluid  and  protein
accumulate within the alveoli, physiologic
shunt develops as blood flows through capillary
units perfusing alveoli that are either filled with
fluid, or have collapsed from the resulting
increase  in  surface  tension.  Hypoxic
vasoconstriction, the normal autoregulatory
reflex severely impaired within the diseased
regions of the lung. Hence, the physiologic
shunt in ARDS is accentuated by increasing of
flow to the poorly ventilated regions of the
lung.37 In addition, increased vasoconstriction
within well-ventilated regions and thrombi that
arise within the microvasculature can both
contribute to the development of physiologic
dead space or wasted ventilation as blood fails
to perfuse the better aerated regions of the
lung.37  The  combined  effects  of  these
derangements result in refractory hypoxemia
and increased minute ventilation needs, helping
to explain the often challenging demands of
managing these patients in the ICU.
Pulmonary vascular resistance is commonly
elevated in patients with ARDS.38,39 This  results
Figure 1: Pathogenesis of ARDS
PMN = polymorphonuclear neutrophils; PAF = platelet-
activating  factor;  IL=interleukin;  GM-CSF  =
Granulocyte-macrophage  colony-stimulating  factor;
C5a = complement component 5a; SIRS = Systemic
inflammatory response syndrome
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from a hypoxia-induced  reduction in the
luminal diameter of the vascular bed, and
thrombotic obstruction of the microvascu-
lature.39,40 This in turn leads to the common
finding of pulmonary hypertension in these
patients, which can alter right ventricular
loading  and  function.   The  decrease  in
respiratory compliance is primarily due to an
increase in lung elastance, particularly in the
more direct forms of ARDS such as pneumonia.
The increased elastic properties of the aerated
lung result from increased tissue stiffness due
to interstitial oedema and increased alveolar
surface tension, but the contribution from
interstitial oedema is thought to be negligible
relative to that from alveolar oedema.41 The
increase in alveolar surface tension is thought
to develop from the increased surface forces
generated by a greater abundance of alveolar
lining fluid  and a decrease in  surfactant
activity.42 The lower resting lung volumes in
ARDS result from persistently fluid-filled or
collapsed alveoli, leading to what has been
colloquially  referred  to  as  baby  lung.43
Unfortunately, the affected regions of the lungs
are often so diseased that they may remain fluid-
filled or completely collapsed throughout each
tidal inflation44 and hence contribute negligibly
to compliance. The unaffected healthy lung
areas are over distended and volutrauma can
occur, this can lead to ventilator associated lung
injury (VALI).32
The predominant histopathologic findings of
ARDS are fundamentally uniform, and it is
diffuse alveolar damage19. It can be further sub-
divided into exudative, proliferative, and
fibrotic phases.19,45 Exudative phase typically
occupies the first week and is characterized by
epithelial  and  endothelial  cell  necrosis,
neutrophil  sequestration,  platelet-fibrin
thrombi, interstitial oedema, and exudates
within the air spaces that consist primarily of
fluid, fibrin, and red blood cells.19 These
exudates compact into dense, protein-rich
hyaline membranes that stain strongly with
eosin and line the alveoli and alveolar ducts.
The proliferative phase starts from second week
to  fourth  week;  it  is  characterized  by
organization of the intra alveolar exudates and
proliferation  of  type  II  alveolar  cells,
fibroblasts, and myofibroblasts. During this
phase, the alveolar ducts are occluded by
metaplastic squamous cells and granulation
tissue.46 The fibrotic phase is seen in patients
who survive past 3 or 4 weeks.19 On histologic
examination, alveolar septa are expanded and
airspaces  filled  with  sparsely  cellular
connective tissue, and remodeling can progress
to the point of complete air space obliteration
and honey combing.46
Clinical features
The signs and symptoms of ARDS can vary in
intensity, depending on its cause and severity.
They include severe shortness of breath,
labored and unusually rapid breathing, low
blood  pressure,  confusion  and  extreme
tiredness. The symptoms of ARDS come on
suddenly, usually within hours or days of the
event that initially caused injury to the lung.
Other symptoms can occur, depending on the
event that caused the ARDS. For example, if
pneumonia is causing the ARDS, symptoms
may also include chest pain and fever.
Frontal chest radiograph shows extensive
bilateral infiltrates. These infiltrates initially
appear as bilateral heterogeneous opacities, but
later become more homogenous over hours to
days.45 computed tomography (CT)  has
demonstrated the distribution of ARDS to often
be heterogeneous and patchy, with mixed
ground-glass opacities and consolidation, often
concentrated in  the more gravitationally
dependent regions of the lung.48
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Magnetic resonance imaging (MRI) has also
been used in the  experimental setting  to
differentiate  between  hydrostatic  and
permeability oedema,49-51 but this method has
also not been widely implemented clinically.
DIAGNOSIS
Berlin definition
A convention in 2011 with an initiative of the
European Society of Intensive Care Medicine
endorsed by the American Thoracic Society and
the Society of Critical Care Medicine develo-
ped the Berlins definition,3 mainly focusing on
feasibility, reliability, validity, and objective
evaluation of its performance. The definition
proposed three mutually exclusive categories
of ARDS based on degree of hypoxaemia: mild
(200 mm Hg < PaO2/FIO2  300 mm Hg),
moderate (100 mm Hg < PaO2/FIO2  200 mm
Hg), and severe (PaO2/FIO2  100 mm Hg) and
four ancilliary variables for severe ARDS:
radiographic severity, respiratory system
compliance ( 40 mL/cm H2O), positive end-
expiratory pressure  (10 cm  H2O),  and
corrected expired volume per minute (10 L/
min). The four ancillary variables did not
contribute to the predictive validity of severe
ARDS for mortality and were removed from
the definition, after it was empirically evaluated
using meta-analysis of 4188 patients with
ARDS from 4 multi-centre clinical data sets
and 269 patients with ARDS from 3 single-
center data  sets containing  physiologic
information. The Berlin definition stages of
mild, moderate, and  severe ARDS  were
associated with increasing mortality (27%,
32%, and 45% respectively) and increasing
median duration of mechanical ventilation in
survivors  (5  days,  7  days  and  9  days
respectively). The final Berlin definition3 had
better  predictive  validity  for  mortality
compared to AECC definition2 with an area
under the receiver-operating characteristic
curve of 0.577 vs 0.536. The updated and
revised Berlin definition for ARDS3 addresses
a  number  of  limitations  of  the  AECC
definition.2 The  approach  of  combining
consensus  discussions  with  empirical
evaluation may serve as a model to create more
accurate,  evidence-based, critical illness
syndrome definitions and to improve clinical
care, research, health service and resource
planning.3
Differential diagnosis
Because the presenting symptoms of ARDS are
non-specific,  other respiratory,  cardiac,
infectious, and toxic aetiologies must be
considered in the differential diagnosis. Patient
history  (e.g., comorbidities,  exposures,
medications) in conjunction with a physical
examination focusing on the respiratory and
cardiovascular systems can help narrow the
differential diagnosis and determine the optimal
course of treatment.
Often, ARDS must be differentiated from
congestive heart  failure and pneumonia.
Congestive heart failure is characterized by
fluid overload, whereas patients diagnosed with
ARDS,  do not  show signs  of left  atrial
hypertension or overt volume overload. Patients
with congestive heart failure may have oedema,
jugular venous distension, third heart sound,
an elevated brain natriuretic peptide level, and
a salutary response to diuretics. Patients with
ARDS would not be expected to have these
findings.52,53
Because pneumonia is a leading cause of
ARDS,  distinguishing  patients  with
uncomplicated pneumonia from those who
have  pneumonia  complicated  by ARDS
presents a greater diagnostic challenge. In
general,  a  patient  with  uncomplicated
pneumonia may have signs of systemic and
pulmonary inflammation (i.e., fever, chills,
fatigue, sputum production, pleuritic chest pain,
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and  localized  or  multifocal  infiltrates);
accompanying hypoxia should respond to
oxygen administration. If hypoxia does not
correct with oxygen administration, ARDS
should be suspected. In those with combined
pneumonia and ARDS, treatment  entails
antibiotics and ventilator management.
TREATMENT
Treatment  of ARDS  includes  definitive
treatment aimed at the underlying aetiological
cause, other supportive measures, mechanical
ventilation, prevention of stress ulcers and
venous thromboembolism, and nutritional
support.
Pharmacologic options for the treatment of
ARDS are limited. Although surfactant therapy
may be helpful in children with ARDS, a
Cochrane review54  did not  find  it to  be
beneficial in adults. The use of corticosteroids
is controversial. Randomized controlled trials
and cohort studies tend to support early use of
corticosteroids (with dosages of methyl-
prednisolone  ranging from 1 to 120 mg per kg
per day) for decreasing the number of days on
a ventilator; however, no consistent mortality
benefit has been shown with this therapy.55,56
In addition to ventilatory measures, patients
with ARDS should receive low-molecular-
weight heparin (40 mg of enoxaparin or 5,000
units of dalteparin subcutaneously per day) or
low-dose, unfractionated heparin (5,000 units
subcutaneously twice daily) to prevent venous
thromboembolism, unless contraindicated.57,58
Patients  should  also  be  on  stress  ulcer
prophylaxis with  an  agent  such as sucralate
(1 g via nasogastric tube four times daily),
ranitidine (150 mg via nasogastric tube twice
daily, 50 mg intravenously every six to eight
hours, or a 6.25 mg per hour continuous
intravenous infusion), or omeprazole (40 mg
intravenously,  or  via  nasogastric  tube
daily)59-62. Finally, patients should receive
nutritional support, preferably enteral, within
24 to 48 hours of admission to the ICU.
Mechanical ventilation
Respiratory failure and hypoxemia are the main
problems  of ARDS. Oxygen delivery by
mechanical  ventilation  remains  a  very
important objective in the management of these
patients. They are more prone for multiorgan
failure.63 Even though higher tidal volume (10
to 15 ml/kg) maintains effective ventilation and
oxygenation, the incidence of VALI was high
in animal models.32,64 Small retrospective and
prospective uncontrolled trials suggested a
benefit from limiting tidal volume and peak
airway pressures in patients with ARDS.65,66
Numerous larger, randomized trials comparing
traditional and lower tidal volumes have since
been conducted, each trial differing in its
methodology and  results.67-71 The  larger
randomized, multicentre trial to date, conducted
by  the  ARDS  Network,  ultimately
demonstrated a  significant reduction  in
mortality when using a tidal volume of 6 mL
per kg of predicted ideal body weight and a
target plateau pressure of 30 cm H2O or less
(mortality 31%) as opposed to a tidal volume
of 12 mL per kg and a target plateau pressure
less than 50 cm H2O (mortality 39.8%).67
Low  tidal  volume  ventilation  improves
outcome by avoiding over distention of normal
alveoli there by preventing volutrauma. Low
tidal volume ventilation also improves outcome
by reduced activation of inflammatory cascades
associated with VILI and multiorgan failure.
In ARDS Network trial studies, it was found
that higher plasma levels of soluble receptors
of  TNF-  were  associated  with  higher
mortality. Furthermore the low tidal volume
strategy was associated with lower levels of
soluble TNF- receptors.51 In another study
from the same patient population, elevated
plasma levels of IL-6, interleukin-8 (IL-8), and
IL-10 were also linked to increased mortality
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while lower tidal volume was associated with
a greater drop in IL-6 and IL-8 by day 3 of
enrolment.73
In low tidal volume ventilation there is a
reduction in minute ventilation causing increase
in partial pressure of arterial carbon dioxide
(PaCO2), which leads to a strategy of permissive
hypercapnia. Some guidelines acknowledge
permissive hypercapnia as an acceptable
practice when necessary to limit tidal volumes,
but also stress that its use is limited in patients
with preexistent  metabolic acidosis,  and
contraindicated in patients with increased
intracranial pressure.74  Because  no  firm
guidelines have  been established, current
options range from a allowing for an arterial
pH as low as 6.8,66 to increasing respiratory rate
up to 35 and buffering with intravenous
bicarbonate when pH  drops below 7.3.67
Despite ongoing controversy75 and the delayed
adoption low tidal volume strategy in clinical
practice,76,77 the current evidence has led
professional societies to recommend the use of
lower tidal volumes at goal plateau pressures
less than 30 cm H2O in patients with established
ARDS.74 Because calculations based on total
body weight may be partly responsible for the
documented underuse of lower tidal volumes
for patients with ARDS,74 the importance of
using predicted ideal body weight (IBW), based
upon measured height and sex, cannot be
overstressed. Although no firm guidelines exist
regarding patients without established ARDS
there is clinical evidence that a low tidal volume
strategy may help prevent progression to ARDS
in patients at risk.78,79 Yet to be determined is
whether a more optimal or “best” strategy exists
beyond that employed in the ARDS Network
sponsored study. Although data suggest that
tidal volumes lower than 6 mL per kg may
confer even greater protection from VILI,80
there is no general consensus on this practice.
However, in the original ARDS Network trial,
the lower tidal volume assignment started with
a goal of 6 mL per kg, but patients in this arm
were oftentimes adjusted to as low as 4 mL per
kg as needed to maintain plateau pressures less
than 30 cm H2O.67
Recruitment
Recruitment manoeuvers (RM) are traditionally
delivered as sustained inflations with peak
inflation pressures limited to between 30 and
40 cm H2O, and held for a period ranging from
15 to 40 seconds.68,81,82 In some patients the
physiologic abnormalities in ARDS can, be
reversed by a recruitment maneuver (RM), and
typically delivered as a sustained deep inflation
with the intention of reopening collapsed
regions of the lung. However, because of the
unusually high surface tension within affected
alveoli, the benefit is often transient,83,84
especially if not followed by sufficiently high
levels of PEEP.85 Periodic RMs also have the
potential to worsen oxygenation by shunting
blood flow to poorly aerated regions86 and
impair cardiac output by limiting venous return
and cardiac preload.81,87 Furthermore, RMs
could conceivably contribute to lung injury
through excessive over distention88 or repeated
opening of collapsed lung.
Many clinical studies have yielded mixed
results regarding beneficial effects of RMs on
oxygenation and lung function.81,83,89 Although
earlier clinical  studies demonstrated  the
benefits of recruitment to be negligible or short-
lived,83,87 recent larger trials have demonstrated
more promising improvements in lung function
and oxygenation but still failed to demonstrate
any reduction in mortality.90,91
Positive end-expiratory pressure
Positive end-expiratory pressure (PEEP) is
another widely employed strategy shown to
retard alveolar derecruitment in the injured
lung. Several studies have demonstrated the
ability of PEEP to prevent or delay alveolar
derecruitment92,93 and attenuate VALI.64,94
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However, the protective effect of higher PEEP
was questioned after a multicentre randomized
trial failed to demonstrate an improvement in
outcomes using a higher PEEP strategy during
low  tidal  volume  ventilation  in  ARDS
patients.95 The amount of recruitable lung varies
significantly among ARDS patients,96 some
have suggested that setting PEEP levels without
first determining the level of recruitable lung
may offset the potential benefits of PEEP. In a
recent randomized trial, the selection of PEEP
was more patient-directed and set at a level
required to maintain plateau pressures of 28 to
30 cm H2O. This higher PEEP strategy again
failed to demonstrate a reduction in mortality,
but did demonstrate lasting improvements in
oxygenation and compliance and an increase
in ventilator-free and organ failure-free days.91
Others have shown that more directly targeting
PEEP to transpulmonary pressure by measuring
esophageal pressures may be a safer and more
effective means of determining optimal PEEP.97
Optimal PEEP
It has been often observed that lower inflection
point (LIP) on the inspiratory limb of the PV
curve obtained from ARDS patients is the point
beyond  which  the  slope  of  the  curve
dramatically increases (Figure 2). This dramatic
increase in compliance at the LIP was initially
believed to represent a sudden increase in lung
volume  and  hence  maximal  alveolar
recruitment. Thus, many have advocated using
the LIP to guide the setting of “optimal”
PEEP.68,98 However, several studies  have
demonstrated significant recruitment beyond
the  LIP,99,100  a  concept  supported  by
mathematical models101 and CT imaging.102,103
Data from CT imaging in ARDS patients has
recently lent strong support to setting “optimal
PEEP” at the point of maximal curvature
(PMC) along the deflation limb of the PV
curve82 (Figure 2). Nevertheless, the concept
of  “optimal  PEEP”  has  likely  been
oversimplified and controversy remains over
how alveolar recruitment is best served by
PEEP.
High frequency oscillation ventilation: High-
frequency oscillation ventilation (HFOV), with
very small tidal volumes equal to or less than
dead space and delivered at a very high rate,
would seem to be an ideal ventilatory strategy
in ARDS. How adequate ventilation is achieved
with tidal volumes less than or equal to dead
space is unknown. Proposed mechanisms
include a pendelluft effect of mixing gases
between lung regions of differing impedances,
coaxial flow with net center inflow and net
peripheral outflow, mixing of fresh and residual
air along the leading edge of gas flow, and
simple molecular diffusion through relatively
still air.104 HFOV first demonstrated clinical
benefits among infants with respiratory distress
syndrome.105,106 Although early smaller studies
of HFOV in adult ARDS were promising,107,108
a larger multicentre-controlled trial failed to
demonstrate any reduction in mortality from
HFOV over conventional ventilation.109
Extracorporeal membrane oxygenation
Extracorporeal  membrane  oxygenation
(ECMO) used alone or in combination with
HFOV, uses  cardiopulmonary bypass  to
facilitate gas exchange while minimizing
ventilation of the lung to limit barriers to
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Figure 2: Pressure volume curves of lung in ARDS
PMC = point of maximal curvature; LIP = lower
inflection point123
healing. Despite demonstrated efficacy in
neonates with severe respiratory distress
syndrome,110 ECMO had until recently failed
to  demonstrate  any  reduction  in  adult
mortality.111,112
Prone position ventilation
Previously in mid 70s, prone positioning was
shown to improve oxygenation in patients with
hypoxic respiratory  failure.113  Proposed
mechanisms have centered around the potential
reversal of gravitationally distributed perfusion
to the better ventilated ventral lung regions114
and  improved  ventilation  of  previously
dependent dorsal lung,115 both of which would
improve ventilation/perfusion matching. The
largest randomized clinical trial to date also
demonstrated an improvement in oxygenation
and a reduced incidence of ventilator-associated
pneumonia with prone positioning, but again
no benefit in survival.116 This study, however,
brought greater attention to safety concerns by
demonstrating a higher incidence in pressure
sores and  inadvertent endotracheal  tube
displacement.
Pharmacological interventions
Vasodilators
Initial  studies  examined  the  use  of
intravenously administered vasodilators such
as nitroglycerin and prostacyclin,117,118 but
simultaneous and nonselective reductions in
systemic and pulmonary vascular resistance led
to systemic arterial hypotension with increases
in cardiac output and shunt. After the once
described “endothelial-derived relaxing factor”
was discovered to be nitric oxide (NO),119 it
was found  that inhaled  NO (iNO) could
selectively dilate the pulmonary vasculature
within well-ventilated regions of the lung,120
helping reverse both hypoxic vasoconstriction
and physiologic shunt. Subsequently, two
small-randomized  controlled  trials
demonstrated a  significant but transient
improvement in oxygenation and shunt in
ARDS patients in response to iNO, but these
benefits did not last past 24 hours, and there
was no improvement in outcomes.121,122 Most
studies have demonstrated minimal adverse
effects of iNO other than dose-dependent
methaemoglobinemia.123At the present time,
iNO has been approved by the Food and Drug
Administration  for use  in neonates  with
hypoxic respiratory failure accompanied by
pulmonary hypertension but is not approved for
use in adult ARDS.
Surfactant
Surfactant replacement is to help restore the
natural surfactant film and reduce surface
tension at the air–liquid interface, thus reducing
the  tendency  for  alveolar  collapse  and
improving oxygenation through a reduction in
shunt. The evidence in support of surfactant
replacement therapy for neonatal RDS is
abundant.124,125 Results from its investigated use
in  adult ARDS  patients  have  been  less
promising.126-128  The  largest  multicentre
randomized clinical trial in adult ARDS failed
to demonstrate any improvement in mortality
with  continuous aerosol  delivery of  the
synthetic surfactant, Exosurf.127
Corticosteroids
Numerous uncontrolled trials had initially
suggested a potential benefit of corticosteroids
for late or persistent ARDS.129-131 However,
treatment with corticosteroids during the acute
phase  of ARDS  has  since  been  proven
ineffective.132,133  The  first  randomized
controlled trial of corticosteroids for late ARDS
demonstrated improved lung injury scores and
oxygenation, decreased multiorgan dysfunction
scores, and reduced  ICU and  in-hospital
mortality in the group receiving steroids.134
Anticoagulants/fibrinolysis
Minimizing microvascular thrombosis could
conceivably improve oxygenation through
improved ventilation-perfusion matching135 and
increase survival  through prevention  of
multiorgan failure.136 Thus, the importance of
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coagulation in the pathogenesis of ARDS has
become widely appreciated,28 and the use of
anticoagulant therapy in ARDS has in turn
gained attention.137 The most encouraging
clinical evidence to support this therapeutic
target initially came from a multicenter trial
demonstrating  a  mortality  benefit  from
activated protein C (APC) in severe sepsis.136
However, because randomized trials of other
potent anticoagulants, such as antithrombin III
and tissue factor pathway inhibitor (TFPI),
yielded no mortality benefit in sepsis,138,139 the
postulated benefits from APC may be unrelated
to its anticoagulant activity.
Nutritional therapy
Nutritional supplements containing omega 3
fatty acids like eicosapentaenoic acids (EPA)
are helpful in directly suppress monocyte
production of inflammatory cytokines and
incorporate into cell membrane phospholipids
to compete with omega-6 fatty acids to promote
the  production  of  more  favorable
prostaglandins and  leukotrienes.140 Many
studies supporting omega-3 fatty acids in
ARDS came initially from small randomized
trials comparing a standard isonitrogenous,
isocaloric enteral diet with one supplemented
with a proprietary mixture of EPA, gamma-
linolenic  acid  (borage  oil),  and  other
antioxidants.141-143 These studies demonstrated
an improvement in gas exchange and lung
function,141,143 a reduction in bronchoalveolar
lavage fluid (BALF) levels of IL-8, leukotriene
B4, and neutrophils,142 and a reduction in ICU
stay and mechanical ventilation days141 with the
EPA-rich supplement.
Fluids
Optimal fluid management in patients with
acute lung injury is unknown. Diuresis or fluid
restriction may improve lung function but could
jeopardize extrapulmonary-organ perfusion.
Although there was no significant difference
in the primary outcome of 60-day mortality, the
conservative strategy of fluid management
improved lung function and shortened the
duration  of  mechanical  ventilation  and
intensive  care  without  increasing
nonpulmonary-organ failures. These results
support the use of a conservative strategy of
fluid management in patients with acute lung
injury.144 Fluids administration is controversial
in ARDS. Liberal fluid administration in these
patients can increase pulmonary oedema.
Limiting fluids in such patients with multi
organ dysfunction can lead to decreased tissue
perfusion.  Diuretic therapy (furosemide)
combined with albumin has been shown to
improve oxygenation and haemodynamics in
hypo-proteinemic ARDS patients but does not
reduce mortality.145 The use of PA catheters
came into question after a large observational
study of 5,700 critically ill patients actually
suggested a higher mortality rate associated
with PA catheter use.146 However, subsequent
prospective trials have contradicted these
findings.147,148 So fluid administration should
be optimized based on haemodynamic stability
and urine output.
Airway pressure release ventilation
Airway pressure release ventilation (APRV) is
a ventilator mode that uses sustained high
airway pressures and spontaneous breathing to
maximize lung recruitment, with transient
periods of “pressure release” to facilitate
ventilation while minimizing derecruitment
during exhalation.149 Proponents assume that
the periods of pressure release are brief enough
to avoid alveolar closure and reexpansion,150
and efficacy relies heavily on the presence of
spontaneous ventilation,151 which is believed
to generate regionally variable transpulmonary
pressures that favor recruitment of dependent
lung regions. 152
Ketoconazole
Ketoconazole acts through inflammatory
signaling modification. It is an imidazole
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antifungal  agent with  anti-inflammatory
properties.  It  blocks  the  synthesis  of
proinflammatory  mediators  such  as  the
eicosanoid leukotrienes and thromboxane A2
and also reduces macrophage proinflammatory
cytokine production.153 Early small studies were
successful in preventing ARDS in high risk
patients,154-156 however a later study by the
ARDSnet group of ketoconazole in 234 patients
with ARDS was negative.157
Ibuprofen
Ibuprofen inhibits cyclo-oxygenase and it is a
non-steroidal anti-inflammatory agent. In a
study of 448 patients with sepsis ibuprofen
diminished prostanoid production and was
associated with trends towards decreased
duration of pulmonary dysfunction and ARDS,
but this did not reach statistical significance.158
Modulation of other inflammatory mediators
has also been investigated.159
Insulin
Insulin has anti-inflammatory effects  via
inhibition of the pro-inflammatory transcription
factor NFkB.160 A landmark trial of intensive
insulin therapy (IIT) in critical care reported a
large decrease in mortality by maintaining
serum glucose levels between 80 and 110 mg/
dL.161 Subsequent critical care studies have had
mixed results,162-164 and a significant risk of
hypoglycaemia was apparent upon meta-
analysis of intensive insulin therapy studies.165
In a rat model of endotoxin induced ARDS tight
glycaemic control to 90-110mg/dl reduced the
severity of lung injury.166 The role of intensive
insulin  therapy  in  preventing ARDS  by
maintaining tight glycaemic control (80 to 110
mg/dL) is currently being studied.
Statins
Apart from their cholesterol lowering effects
statins improve epithelial and endothelial
function  to  reduce  alveolar  capillary
permeability and decrease pulmonary oedema.
Statins modulate the inflammatory cascade;
regulate  inflammatory  cell  recruitment,
activation and apoptosis; and lessen cytokine
and protease activity.167 This may improve
outcomes, as high levels and persistence of
inflammatory  mediators  in  ARDS  are
associated with poor outcome.168
Others
IL-8 is a chemoattractant for neutrophil
migration into the alveolus.169 In a rat model of
gastric  aspiration  anti-IL-8  antibody
significantly reduced neutrophil recruitment to
the alveolus and reduced the severity of lung
injury.170
ARDS is a process of diffuse pulmonary
inflammation with increased vascular and
alveolar permeability.  The physiologic process
is restrictive lung disease and hypoxemia
occurs due to oedema and V/Q mismatch. The
ventilatory treatment involves increasing
positive pressure  ventilation to  improve
oxygenation. Ventilator induced lung injury can
be minimized by maintaining high PEEP, low
tidal volume, peak pressures less than 35 cm
H2O,  and FiO2 less than  60%. Death is
primarily due to multi-organ dysfunction
(usually cardiovascular collapse), and not
ARDS  primarily.    Therefore,  all  other
supportive measures should be optimized.
Since its first published description in 1967,1
our understanding of the pathogenesis and
pathophysiology  of  ARDS  has  grown
appreciably, and ongoing research efforts
continue to provide hope for exciting new
therapies  in  the  future.  The  improved
understanding of this condition has already
resulted in improved outcomes for patients
suffering from ARDS16, but the prognosis for
those acutely afflicted in the hospital,5 and those
fortunate enough to survive,171 leaves room for
ongoing progress in the management of these
patients. Aside from the obvious importance
of reducing mortality from this condition, a
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reduction in  days on  the ventilator  and
subsequent stay in the intensive care unit
represent some of the other tangible and
intangible benefits to both patients and society
in general.172,173
REFERENCES
1. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE.
Acute  respiratory distress  in adults.  Lancet
1967;2:319-23.
2. Bernard GR, Artigas A, Brigham KL, Carlet J,
Falke K, Hudson L, et al. The American-European
Consensus Conference on ARDS. Definitions,
mechanisms, relevant outcomes, and clinical trial
coordination. Am  J Respir  Crit  Care  Med
1994;149:818-24.
3. Ranieri VM, Rubenfeld  GD, Thompson BT,
Ferguson ND, Caldwell E, Fan E, et al. ARDS
Definition Task Force. The Berlin Definition.
JAMA 2012;307:2526-33.
4. Goss CH, Brower RG, Hudson LD, Rubenfeld GD.
ARDS Network. Incidence of acute lung injury in
the united states. Crit Care Med 2003;31:1607-
11.
5. Rubenfeld GD, Caldwell E, Peabody E, Weaver
J, Martin  DP, Neff  M, et al. Incidence  and
outcomes of acute lung injury.  N Engl J Med
2005;353:1685-93.
6. Luhr OR, Antonsen K, Karlsson M, Aardal S,
Thorsteinsson A, Frostell CG, et al. Incidence and
mortality after acute respiratory failure and acute
respiratory  distress  syndrome in  Sweden,
Denmark, and Iceland. The ARF study group. Am
J Respir Crit Care Med 1999;159:1849-61.
7. Villar J, Blanco J, Anon JM, Santos-Bouza A,
Blanch L, Ambros A, et al. The ALIEN study:
incidence and outcome of acute respiratory distress
syndrome in the era of lung protective ventilation.
Intensive Care Med 2011;37:1932-41.
8. Bersten AD, Edibam  C, Hunt T,  Moran  J.
Australian and New Zealand Intensive Care
Society Clinical Trials Group. Incidence and
mortality of acute lung injury and the acute
respiratory distress syndrome in three Australian
states.  Am  J  Respir  Crit  Care  Med
2002;165:443-8.
9. Ware LB, Matthay MA. The acute respiratory
distress syndrome. N Engl J Med 2000;342:1334-
49.
10. TenHoor T, Mannino DM, Moss M. Risk factors
for ARDS in the United States: analysis of the 1993
National Mortality  Followback Study. Chest
2001;119:1179-84.
11. Hudson LD, Milberg JA, Anardi D, Maunder RJ.
Clinical risks for development of the acute
respiratory distress syndrome. Am J Respir Crit
Care Med 1995;151:293-301.
12. Zilberberg MD, Epstein SK. Acute lung injury in
the medical ICU: comorbid conditions, age,
etiology, and hospital outcome. Am J Respir Crit
Care Med 1998;157:1159-64.
13. Mohan A, Sharma SK, Bollineni S. Acute lung
injury and acute respiratory distress syndrome in
malaria. J Vector Borne Dis 2008;45:179-93.
14. Limaye CS, Londhey VA, Nabar ST. The study of
complications of vivax malaria in comparison with
falciparum malaria in Mumbai. J Assoc Physicians
India 2012 ;60:15-8.
15. Bhattacharjee P, Dubey S, Gupta VK, Agarwal P,
Mahato MP. The clinicopathologic manifestations
of Plasmodium vivax malaria in children: a
growing menace. J Clin Diagn Res 2013;7:861-7.
16. Milberg JA, Davis DR, Steinberg KP, Hudson LD.
Improved  survival  of  patients  with  acute
respiratory distress syndrome (ARDS): 1983–
1993. JAMA 1995;273:306-9.
17. Wioedemann HP, Wheeler AP, Bernard GR,
Thompson BT, Hayden D, deBoisblanc B, et al.
National Heart, Lung and Blood Institute Acute
Respiratory Distress Syndrome (ARDS) Clinical
Trails  Network. Comparison  of two  fluid-
management strategies in acute lung injury. N Engl
J Med 2006;354:2564-75.
18. Wheeler AP, Bernard  GR, Thompson  BT,
Schoenfeld D, Wioedemann HP, deBoisblanc B,
et al. National Heart, Lung and Blood Institute
Acute Respiratory Distress Syndrome (ARDS)
Clinical Trails Network. Pulmonary-artery versus
central venous catheter to guide treatment of  acute
lung injury. N Engl J Med 2006;354:2213-24.
19. Tomashefski JF Jr: Pulmonary pathology of acute
respiratory distress syndrome. Clin Chest Med
2000;21:435-66.
Acute respiratory distress syndrome Rao et al127
20. Bachofen M, Weibel ER. Structural alterations of
lung parenchyma in the adult respiratory distress
syndrome. Clin Chest Med 1982;3:35-56.
21. Martin TR, Nakamura M, Matute-Bello G. The
role of apoptosis in acute lung injury. Crit Care
Med 2003;31:S184-8.
22. Abraham E. Neutrophils and acute lung injury. Crit
Care Med 2003;31:S195-9.
23. Hastings  RH, Folkesson  HG, Matthay  MA.
Mechanisms of alveolar protein clearance in the
intact lung. Am J Physiol 2004;286:L679-89.
24. Ribes JA, Francis CW, Wagner DD: Fibrin induces
release of von Willebrand factor from endothelial
cells. J Clin Invest 1987;79:117-23.
25. Strieter RM, Kunkel SL, Showell HJ, Remick DG,
Phan SH, Ward P, et al. Endothelial cell gene
expression of a neutrophil chemotactic factor by
TNF-alpha,  LPS,  and  IL-1  beta.  Science
1989;243:1467-9.
26. Rubin DB, Wiener-Kronish JP, Murray JF, Green
DR, Turner J, Luce  JM, et  al. Elevated von
Willebrand factor antigen is an early plasma
predictor of acute lung injury in nonpulmonary
sepsis syndrome. J Clin Invest 1990;86:474-80.
27. Ware LB, Eisner MD, Thompson BT, Parsons PE,
Matthay MA. Significance of von Willebrand
factor in septic and nonseptic patients with acute
lung  injury. Am  J  Respir  Crit  Care  Med
2004;170:766-72.
28. Idell S. Coagulation, fibrinolysis, and fibrin
deposition in acute lung injury. Crit Care Med
2003;31:S213-20.
29. Abraham E. Coagulation abnormalities in acute
lung injury and sepsis. Am J Respir Cell Mol Biol
2000;22:401-4.
30. Brigham KL, Meyrick B. Endotoxin and lung
injury. Am Rev Respir Dis 1986;133:913-27.
31. Imai Y, Parodo J, Kajikawa O, de Perrot M, Fischer
S,  Edwards V, et  al.  Injurious  mechanical
ventilation and end-organ epithelial cell apoptosis
and organ dysfunction in an experimental model
of acute respiratory distress syndrome. JAMA
2003;289:2104-12.
32. Dreyfuss D, Saumon G. Ventilator-induced lung
injury: lessons from experimental studies. Am J
Respir Crit Care Med 1998;157:294-323.
33. Matthay MA, Bhattacharya S, Gaver D, Ware LB,
Lim LH, Syrkina O, et al. Ventilator-induced lung
injury: in vivo and in vitro mechanisms. Am J
Physiol 2002;283:L678-82.
34. Bhatia M, Moochhala S. Role of inflammatory
mediators  in the  pathophysiology of  acute
respiratory  distress  syndrome.  J  Pathol
2004;202:145-56.
35. Piantadosi  CA,  Schwartz  DA.  The  acute
respiratory distress syndrome. Ann Intern Med
2004;141:460-70.
36. Schiller HJ, McCann UG 2nd, Carney DE, Gatto
LA, Steinberg JM, Nieman GF. Altered alveolar
mechanics in the acutely injured lung. Crit Care
Med 2001;29:1049-55.
37. Kaisers U, Busch T, Deja M, Donaubauer B, Falke
KJ. Selective pulmonary vasodilation in acute
respiratory distress syndrome. Crit Care Med
2003;31:S337-42.
38. Zapol WM, Snider MT. Pulmonary hypertension
in severe acute respiratory failure. N Engl J Med
1977;296:476-80.
39. Villar J, Blazquez MA, Lubillo S,Quintana J,
Manzano JL. Pulmonary hypertension in acute
respiratory  failure.  Crit  Care  Med
1989;17:523-6.
40. Zapol WM, Kobayashi K, Snider MT, Greene R,
Laver MB. Vascular obstruction causes pulmonary
hypertension in severe acute respiratory failure.
Chest 1977;71:306-7.
41. Horie T, Hildebrandt J. Dynamic compliance, limit
cycles, and static equilibria of excised cat lung. J
Appl Physiol 1971;31:423-30.
42. Petty TL, Reiss OK, Paul GW, Slivers GW, Elkins
ND. Characteristics of pulmonary surfactant in
adult respiratory distress syndrome associated with
trauma  and  shock.  Am  Rev  Respir  Dis
1977;115:531-6.
43. Gattinoni L, Caironi P, Pelosi P, Goodman LR.
What has computed tomography taught us about
the acute respiratory distress syndrome? Am J
Respir Crit Care Med 2001;164:1701-11.
44. Hubmayr RD. Perspective on lung injury and
recruitment: a skeptical look at the opening and
collapse  story. Am  J Respir  Crit Care Med
2002;165:1647-53.
Acute respiratory distress syndrome Rao et al128
45. Blennerhassett JB. Shock lung and diffuse alveolar
damage  pathological  and  pathogenetic
considerations. Pathology 1985;17:239-47.
46. Cheung O, Leslie KO: Acute Lung Injury, in Leslie
KO, Wick MW  (eds): Practical  Pulmonary
Pathology. Philadelphia, Churchill Livingstone,
2005 pp 71-95.
47. Goodman  PC,  Quinones  Maymi  DM.
Radiographic findings in ARDS, In Matthay MA,
editor: Acute respiratory distress syndrome. New
York: Marcel Dekker, Inc; 2003; Inc, 55-73.
48. Tagliabue M, Casella TC, Zincone GE, Fumagalli
R, Salvini E. CT and chest radiography in the
evaluation of adult respiratory distress syndrome.
Acta Radiol 1994;35:230-4.
49. Kaplan JD, Calandrino FS, Schuster DP. A positron
emission tomographic comparison of pulmonary
vascular permeability during the adult respiratory
distress syndrome and pneumonia. Am Rev Respir
Dis 1991;143:150-4.
50. Berthezene Y, Vexler V, Jerome H, Sievers R,
Moseley  ME, Brasch RC. Differentiation  of
capillary leak and hydrostatic pulmonary oedema
with a macromolecular MR imaging contrast
agent. Radiology 1991;181:773-7.
51. Raijmakers PG, Groeneveld AB, Teule GJ, Thijs
LG. Diagnostic value of the gallium-67 pulmonary
leak index in pulmonary oedema. J Nucl Med
1996;37:1316-22.
52. McMurray JJ. Clinical practice. Systolic heart
failure. N Engl J Med 2010;362:228-38.
53. Mandell LA, Wunderink RG, Anzueto A, Bartlett
JG, Campbell GD, Dean NC, et al. Infectious
Diseases Society of America/American Thoracic
Society consensus guidelines on the management
of community-acquired pneumonia in adults. Clin
Infect Dis 2007;44:S27-72.
54. Adhikari  N,  Burns  KE,  Meade  MO.
Pharmacologic therapies for adults with acute lung
injury and acute respiratory distress syndrome.
Cochrane Database Syst Rev 2004;4:CD004477.
55. Peter JV, John P, Graham PL, Moran JL, George
IA, Bersten A. Corticosteroids in the prevention
and  treatment of  acute respiratory  distress
syndrome (ARDS) in adults: meta-analysis. BMJ
2008;336:1006-9.
56. Tang BM, Craig JC, Eslick GD, Seppelt I, McLean
AS. Use of corticosteroids in acute lung injury and
acute respiratory distress syndrome: a systematic
review  and  meta-analysis.  Crit  Care  Med
2009;37:1594-603.
57. Geerts WH, Bergqvist D, Pineo GF, Heit JA,
Samama CM, Lassen MR, et al. Prevention of
venous thromboembolism: American College of
Chest Physicians evidence-based clinical practice
guidelines. 8th edition Chest 2008;133:381S-
453S.
58. Jobin S, et al. Health care guideline: venous
thromboembolism  prophylaxis. 8th  edition.
Bloomington, Minn.: Institute for Clinical Systems
Improvement; 2010. Available at URL: http://
www.icsi.org/guidelines_and_more/gl_os_prot/
cardiovascular/. Accessed March 5, 2014.
59. Cook DJ, Fuller HD, Guyatt GH, Marshall JC,
Leasa  D,  Hall  R,  et  al.  Risk  factors  for
gastrointestinal bleeding in critically ill patients.
Canadian Critical Care Trials Group. N Engl J Med
1994;330:377-81.
60. Goodwin CM, Hoffman JA. Deep vein thrombosis
and stress ulcer prophylaxis in the intensive care
unit. J Pharm Pract 2011;24:78-88.
61. Guillamondegui OD, Gunter OL Jr, Bonadies JA,
et al.; EAST Practice Management Guidelines
Committee. Practice management guidelines for
stress ulcer prophylaxis. Chicago, Ill.: Eastern
Association for the Surgery of Trauma (EAST);
2008. Available at URL: http://www.east.org/
research/treatment-guidelines/stress-ulcer-
prophylaxis. Accessed March 5, 2014.
62. Lin PC, Chang CH, Hsu PI, Tseng PI, Huang YB.
The efficacy and safety of proton pump inhibitors
vs histamine-2 receptor antagonists for stress ulcer
bleeding prophylaxis among critical care patients:
a meta-analysis. Crit Care Med 2010;38:1197-205.
63. Stapleton RD, Wang BM, Hudson LD, Rubenfeld
GD, Caldwell ES, Steinberg KP.  Causes and
timing of death in patients with ARDS. Chest
2005;128:525-32.
64. Webb HH, Tierney DF. Experimental pulmonary
oedema due to intermittent positive  pressure
ventilation with high inflation pressures. Protection
by positive end-expiratory pressure. Am Rev
Respir Dis 1974;110:556-65.
65. Hickling KG, Henderson SJ, Jackson R. Low
mortality associated with low volume pressure
Acute respiratory distress syndrome Rao et al129
limited ventilation with permissive hypercapnia in
severe adult  respiratory distress  syndrome.
Intensive Care Med 1990;16:372-7.
66. Hickling KG, Walsh J, Henderson S, Jackson R.
Low mortality rate in adult respiratory distress
syndrome using low-volume, pressure-limited
ventilation with  permissive hypercapnia:  a
prospective study. Crit Care Med 1994;22:1568-
78.
67. ARDS-Network. Ventilation  with lower tidal
volumes  as compared  with traditional  tidal
volumes  for acute lung injury and the acute
respiratory  distress  syndrome. The Acute
Respiratory Distress Syndrome Network. N Engl
J Med 2000;342:1301-8.
68. Amato MB, Barbas CS, Medeiros DM, Magaldi
RB, Schettino GP, Lorenzi-Filho G, et al. Effect
of a protective-ventilation strategy on mortality in
the acute respiratory distress syndrome. N Engl J
Med 1998;338:347-54.
69. Brochard  L, Roudot-Thoraval  F, Roupie  E,
Delclaux C, Chastre J, Fernandez-Mondéjar E, et
al. Tidal volume reduction for prevention of
ventilator-induced lung injury in acute respiratory
distress syndrome. The Multicenter Trial Group
on Tidal Volume reduction in ARDS. Am J Respir
Crit Care Med 1998;158:1831-8.
70. Brower RG, Shanholtz CB, Fessler HE, Shade
DM, White P Jr, Wiener CM, et al. Prospective,
randomized, controlled clinical trial comparing
traditional versus reduced tidal volume ventilation
in acute respiratory distress syndrome patients. Crit
Care Med 1999;27:1492-8.
71. Stewart TE, Meade MO, Cook DJ, Granton JT,
Hodder RV, Lapinsky SE, et al. Evaluation of a
ventilation strategy to prevent barotrauma in
patients at high risk for acute respiratory distress
syndrome.  Pressure-  and  Volume-Limited
Ventilation Strategy  Group. N  Engl J  Med
1998;338:355-61.
72. Parsons PE, Matthay MA, Ware LB, Eisner MD.
Elevated plasma levels of soluble TNF receptors
are associated with morbidity and mortality in
patients with acute lung injury. Am J Physiol Lung
Cell Mol Physiol 2004;288:L426-31.
73. Parsons PE, Eisner MD, Thompson BT, Matthay
MA, Ancukiewicz M, Bernard GR, et al. Lower
tidal volume ventilation and plasma cytokine
markers of inflammation in patients with acute lung
injury. Crit Care Med 2005;33:1-6; discussion
230-2.
74. Dellinger RP, Carlet JM, Masur H, Gerlach H,
Calandra T, Cohen J, et al. Surviving Sepsis
Campaign guidelines for management of severe
sepsis  and  septic  shock.  Crit  Care  Med
2004;32:858-73.
75. Eichacker PQ, Gerstenberger EP, Banks SM, Cui
X, Natanson C. Meta-analysis of acute lung injury
and acute respiratory distress syndrome trials
testing low tidal volumes. Am J Respir Crit Care
Med 2002;166:1510-4.
76. Young MP, Manning HL, Wilson DL, Mette SA,
Riker RR, Leiter JC, et al. Ventilation of patients
with acute lung injury and acute respiratory
distress syndrome: has new evidence changed
clinical practice? Crit Care Med 2004;32:1260-5.
77. Kalhan R, Mikkelsen M, Dedhiya P, Christie J,
Gaughan C, Lanken PN, et al. Underuse of lung
protective ventilation: analysis of potential factors
to explain physician behavior. Crit Care Med
2006;34:300-6.
78. Gajic O, Dara SI, Mendez JL, Adesanya AO, Festic
E, Caples SM, et al. Ventilator-associated lung
injury in patients without acute lung injury at the
onset of mechanical ventilation. Crit Care Med
2004;32:1817-24.
79. Yilmaz M, Keegan MT, Iscimen R, Afessa B, Buck
CF, Hubmayr RD, et al. Toward the prevention of
acute lung injury: protocol-guided limitation of
large tidal volume ventilation and inappropriate
transfusion. Crit Care Med 2007;35:1660-6.
80. Frank JA, Gutierrez JA, Jones KD, Allen L, Dobbs
L, Matthay MA.  Low  tidal volume reduces
epithelial and endothelial injury in acid-injured rat
lungs.  Am  J  Respir  Crit  Care  Med
2002;165:242-9.
81. Brower RG, Morris A, MacIntyre N, Matthay MA,
Hayden  D, Thompson  T,  et  al. Effects  of
recruitment maneuvers in patients with acute lung
injury and acute respiratory distress syndrome
ventilated with high positive end-expiratory
pressure. Crit Care Med 2003;31:2592-7.
82. Fujino Y, Goddon S, Dolhnikoff M, Hess D, Amato
MB, Kacmarek RM. Repetitive high-pressure
recruitment maneuvers required to maximally
recruit lung in a sheep model of acute respiratory
distress  syndrome.  Crit  Care  Med
2001;29:1579-86.
Acute respiratory distress syndrome Rao et al130
83. Oczenski W, Hormann C, Keller C, Lorenzl N,
Kepka A, Schwarz S,  et al. Recruitment maneuvers
after a positive end-expiratory pressure trial do
not  induce  sustained effects  in  early  adult
respiratory distress syndrome. Anesthesiology
2004;101:620-5.
84. Allen G, Lundblad LK, Parsons P, Bates  H.
Transient mechanical benefits of a deep inflation
in  the injured  mouse lung.  J Appl  Physiol
2002;93:1709-15.
85. Lim CM, Jung H, Koh Y, Lee JS, Shim TS, Lee
SD, et al. Effect of alveolar recruitment maneuver
in early acute respiratory distress syndrome
according to antiderecruitment strategy, etiological
category of diffuse lung injury, and body position
of the patient. Crit Care Med 2003;31:411-8.
86. Musch G, Harris RS, Vidal Melo MF, O’Neill KR,
Layfield JD, Winkler T, et al. Mechanism by which
a sustained inflation can worsen oxygenation in
acute  lung  injury.  Anesthesiology
2004;100:323-30.
87. Brower RG, Morris A, MacIntyre N, Matthay MA,
Hayden  D, Thompson  T,  et  al. Effects  of
recruitment maneuvers in patients with acute lung
injury and acute respiratory distress syndrome
ventilated with high positive end-expiratory
pressure. Crit Care Med 2003;31:2592-7.
88. Lim CM, Soon Lee S, Seoung Lee J, Koh Y, Sun
Shim T, Do Lee S, et al. Morphometric effects of
the recruitment maneuver on saline-lavaged canine
lungs. A  computed  tomographic  analysis.
Anesthesiology 2003;99:71-80.
89. Foti G, Cereda M, Sparacino ME, De Marchi L,
Villa  F, Pesenti A. Effects of periodic  lung
recruitment maneuvers on gas exchange and
respiratory mechanics in mechanically ventilated
acute respiratory distress syndrome (ARDS)
patients. Intensive Care Med 2000;26:501-7.
90. Meade MO, Cook DJ, Guyatt GH, Slutsky AS,
Arabi YM, Cooper DJ, et al. Ventilation strategy
using low tidal volumes, recruitment maneuvers,
and high positive end-expiratory pressure for acute
lung  injury and  acute  respiratory  distress
syndrome: a randomized controlled trial. JAMA
2008;299:637-45.
91. Mercat A, Richard JC, Vielle B, Jaber S, Osman
D, Diehl JL, et al. Positive end-expiratory pressure
setting in adults with acute lung injury and acute
respiratory distress syndrome: a randomized
controlled trial. JAMA 2008;299:646-55.
92. Halter JM, Steinberg JM, Schiller HJ, DaSilva M,
Gatto LA, Landas S, et al. Positive end-expiratory
pressure after a recruitment maneuver prevents
both  alveolar  collapse  and  recruitment/
derecruitment. Am  J Respir Crit Care  Med
2003;167:1620-6.
93. Gattinoni L, D’Andrea L, Pelosi P, Vitale G,
Pesenti A, Fumagalli R. Regional effects and
mechanism of positive end-expiratory pressure in
early adult respiratory distress syndrome. JAMA
1993;269:2122-7.
94. Tremblay L, Valenza F, Ribeiro SP, Li J, Slutsky
AS. Injurious Ventilatory Strategies increase
cytokines and c-fos m-RNA expression in an
iosolated  rat  lung  model.  J  Clin  Invest
1997;99:944-52.
95. Brower RG, Lanken PN, MacIntyre N, Matthay
MA, Morris A, Ancukiewicz M, et al. Higher
versus lower positive end-expiratory pressures in
patients  with the  acute respiratory distress
syndrome. N Engl J Med 2004;351:327-36.
96. Gattinoni L, Caironi P, Cressoni M, Chiumello D,
Ranieri VM, Quintel M, et al. Lung recruitment in
patients  with the  acute respiratory distress
syndrome. N Engl J Med 2006;354:1775-86.
97. Talmor D, Sarge T, Malhotra A, O’Donnell CR,
Ritz R, Lisbon A, et al. Mechanical ventilation
guided by esophageal pressure in acute lung injury.
N Engl J Med 2008;359:2095-104.
98. Amato MB, Barbas CS, Medeiros DM, Schettino
Gde P, Lorenzi Filho G, Kairalla  RA, et al.
Beneficial effects of the “open lung approach” with
low distending pressures in acute respiratory
distress syndrome. A prospective randomized
study on mechanical ventilation. Am J Respir Crit
Care Med 1995;152:1835-46.
99. Maggiore SM, Jonson B, Richard JC, Jaber S,
Lemaire F, Brochard L. Alveolar derecruitment at
decremental positive end-expiratory pressure
levels in acute lung injury: comparison with the
lower  inflection  point,  oxygenation,  and
compliance. Am  J  Respir  Crit  Care  Med
2001;164:795-801.
100. Jonson B, Richard JC, Straus C, Mancebo J,
Lemaire F, Brochard L.  Pressure-volume curves
and compliance in acute lung injury. Evidence of
recruitment above the lower inflection point. Am
J Respir Crit Care Med 1999;159:1172-8.
Acute respiratory distress syndrome Rao et al131
101. Hickling KG. The pressure-volume curve is greatly
modified by recruitment. A mathematical model
of ARDS lungs. Am J Respir Crit Care Med
1998;158:194-202.
102. Gattinoni L, Pesenti A, Avalli L, Rossi F, Bombino
M.  Pressure-volume curve of total respiratory
system in acute respiratory failure. Computed
tomographic scan study. Am Rev Respir Dis
1987;136:730-6.
103. Albaiceta GM, Taboada F, Parra D, Luyando LH,
Calvo J, Menendez R, et al. Tomographic study
of the inflection points of the pressure-volume
curve in acute lung injury. Am J Respir Crit Care
Med 2004;170:1066-72.
104. Moss M, Parsons PE. Mechanical ventilation and
the adult respiratory distress syndrome. Semin
Respir Crit Care Med 1994;15:289-99.
105. Gerstmann  DR, Minton  SD, Stoddard  RA,
Meredith KS, Monaco F, Bertrand JM, et al. The
Provo multicenter early high-frequency oscillatory
ventilation trial: improved pulmonary and clinical
outcome in  respiratory distress  syndrome.
Pediatrics 1996;98:1044-57.
106. High-frequency oscillatory ventilation compared
with conventional mechanical ventilation in the
treatment of respiratory failure in preterm infants.
The  HIFI  Study  Group.  N  Engl  J  Med
1989;320:88-93.
107. Mehta S, Lapinsky SE, Hallett DC, Merker D,
Groll RJ, Cooper AB, et al. Prospective trial of
high-frequency oscillation in adults with acute
respiratory distress syndrome. Crit Care Med
2001;29:1360-9.
108. Fort P, Farmer C, Westerman J, Johannigman J,
Beninati W,  Dolan S, et al.  High-frequency
oscillatory ventilation for adult respiratory distress
syndrome–a  pilot  study.  Crit  Care  Med
1997;25:937-47.
109. Derdak S, Mehta S, Stewart TE, Smith T, Rogers
M, Buchman TG, et al. High-frequency oscillatory
ventilation for acute respiratory distress syndrome
in adults: a randomized, controlled trial. Am J
Respir Crit Care Med 2002;166:801-8.
110. UK collaborative randomised trial of neonatal
extracorporeal  membrane oxygenation.  UK
Collaborative ECMO  Trial  Group.  Lancet
1996;348:75-82.
111. Morris AH, Wallace CJ, Menlove RL, Clemmer
TP, Orme JF Jr, Weaver LK, et al. Randomized
clinical trial of pressure-controlled inverse ratio
ventilation and extracorporeal carbon dioxide
removal for adult respiratory distress syndrome.
Am J Respir Crit Care Med 1994;149:295-305.
112. Zapol WM, Snider MT, Hill JD, Fallat RJ, Bartlett
RH, Edmunds LH, et al. Extracorporeal membrane
oxygenation in severe acute respiratory failure. A
randomized  prospective  study.  JAMA
1979;242:2193-6.
113. Douglas WW, Rehder K, Beynen FM, Fallat RJ,
Bartlett RH,  Edmunds LH,  et al.  Improved
oxygenation in patients with acute respiratory
failure: the prone position. Am Rev Respir Dis
1977;115:559-66.
114. Wiener CM, Kirk W, Albert RK. Prone position
reverses gravitational distribution of perfusion in
dog lungs with oleic acid-induced injury. J Appl
Physiol 1990;68:1386-92.
115. Lamm WJ, Graham MM, Albert RK. Mechanism
by which the prone position improves oxygenation
in acute lung injury. Am J Respir Crit Care Med
1994;150:184-93.
116. Guerin C, Gaillard S, Lemasson S, Ayzac L, Girard
R, Beuret P, et al. Effects of systematic prone
positioning in hypoxemic acute respiratory failure:
a  randomized  controlled  trial.  JAMA
2004;292:2379-87.
117. Radermacher P, Santak B, Becker H, Falke KJ.
Prostaglandin E1  and  nitroglycerin  reduce
pulmonary  capillary  pressure  but  worsen
ventilation-perfusion distributions in patients with
adult  respiratory  distress  syndrome.
Anesthesiology 1989;70:601-6.
118. Colley PS, Cheney FW Jr, Hlastala MP. Pulmonary
gas exchange effects of nitroglycerin in canine
oedematous  lungs.  Anesthesiology
1981;55:114-9.
119. Palmer RM, Ferrige AG, Moncada S. Nitric oxide
release accounts for the biological activity of
endothelium-derived  relaxing factor.  Nature
1987;327:524-6.
120. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT,
Stone D, Wallwork J. Inhaled nitric oxide as a
cause of selective pulmonary vasodilatation in
pulmonary hypertension.Lancet1991;338:1173-4.
Acute respiratory distress syndrome Rao et al132
121. Troncy E, Collet JP, Shapiro S, Guimond JG, Blair
L, Ducruet T, et al. Inhaled nitric oxide in acute
respiratory distress syndrome: a pilot randomized
controlled study. Am J Respir Crit Care Med
1998;157:1483-8.
122. Michael JR, Barton RG, Saffle JR, Mone M,
Markewitz BA, Hillier K, et al. Inhaled nitric oxide
versus conventional therapy: effect on oxygenation
in  ARDS.  Am  J  Respir  Crit  Care  Med
1998;157:1372-80.
123. Dellinger RP, Zimmerman JL, Taylor RW, Straube
RC, Hauser DL, Criner GJ, et al. Effects of inhaled
nitric oxide in patients with acute respiratory
distress syndrome: results of a randomized phase
II trial. Inhaled Nitric Oxide in ARDS Study
Group. Crit Care Med 1998;26:15-23.
124. Early versus delayed neonatal administration of a
synthetic surfactant–the judgment of OSIRIS. The
OSIRIS  Collaborative Group  (open study  of
infants  at high  risk of  or with  respiratory
insufficiency—the role of surfactant). Lancet
1992;340:1363-9.
125. Schwartz RM, Luby AM, Scanlon JW, Kellogg
RJ. Effect of surfactant on morbidity, mortality,
and resource use in newborn infants weighing 500
to 1500 g. N Engl J Med 1994;330:1476-80.
126. Spragg RG, Lewis JF, Walmrath HD, Johannigman
J, Bellingan G, Laterre PF,   et  al. Effect  of
recombinant surfactant protein C-based surfactant
on the acute respiratory distress syndrome. N Engl
J Med 2004;351:884-92.
127. Anzueto A, Baughman RP, Guntupalli KK, Weg
JG, Wioedemann  HP, Raventós AA,  et  al.
Aerosolized surfactant in adults with sepsis-
induced acute  respiratory distress  syndrome.
Exosurf Acute Respiratory Distress Syndrome
Sepsis  Study  Group.  N  Engl  J  Med
1996;334:1417-21.
128. Spragg RG, Richman P, Gilliard N, Merritt TA,
Robertson B, Curstedt T. The use of exogenous
surfactant to treat patients with acute high-
permeability lung oedema. Prog Clin Biol Res
1989;308:791-6.
129. Meduri GU, Chinn AJ, Leeper KV, Wunderink RG,
Tolley E, Winer-Muram HT, et al. Corticosteroid
rescue treatment of progressive fibroproliferation
in late ARDS. Patterns of response and predictors
of outcome. Chest 1994;105:1516-27.
130. Meduri GU, Belenchia JM, Estes RJ, Wunderink
RG, el Torky M, Leeper KV Jr.  Fibroproliferative
phase of ARDS. Clinical findings and effects of
corticosteroids. Chest 1991;100:943-52.
131. Hooper RG, Kearl RA. Established ARDS treated
with a sustained course of adrenocortical steroids.
Chest 1990;97:138-43.
132. Luce JM, Montgomery AB, Marks JD, Turner J,
Metz CA, Murray JF.  Ineffectiveness of high-dose
methylprednisolone in preventing parenchymal
lung injury and improving mortality in patients
with  septic  shock.  Am  Rev  Respir  Dis
1988;138:62-8.
133. Bernard GR, Luce JM, Sprung CL, Rinaldo JE,
Tate  RM,  Sibbald  WJ,  et  al.  High-dose
corticosteroids  in  patients  with  the  adult
respiratory distress syndrome. N Engl J Med
1987;317:1565-70.
134. Meduri GU, Headley AS, Golden E, Carson SJ,
Umberger RA, Kelso T, et al. Effect of prolonged
methylprednisolone therapy in unresolving acute
respiratory distress syndrome: a randomized
controlled trial. JAMA 1998;280:159-65.
135. Welty-Wolf KE, Carraway MS, Miller DL, Ortel
TL, Ezban M, Ghio AJ, et al. Coagulation blockade
prevents sepsis-induced respiratory and renal
failure in baboons. Am J Respir Crit Care Med
2001;164:1988-96.
136. Bernard GR, Vincent JL, Laterre PF, LaRosa SP,
Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy
and safety of recombinant human activated protein
C for severe sepsis. N Engl J Med 2001;344:699-
709.
137. Laterre  PF,  Wittebole  X,  Dhainaut  JF.
Anticoagulant therapy in acute lung injury. Crit
Care Med 2003;31:S329-36.
138. Abraham E, Reinhart K, Opal S, Demeyer I, Doig
C, Rodriguez AL, et al. Efficacy and safety of
tifacogin (recombinant tissue factor pathway
inhibitor) in severe sepsis: a randomized controlled
trial. JAMA 2003;290:238-47.
139. Warren BL, Eid A, Singer P, Pillay SS, Carl P,
Novak I, et al. Caring for the critically ill patient.
High-dose antithrombin III in severe sepsis: a
randomized  controlled  trial.  JAMA
2001;286:1869-78.
Acute respiratory distress syndrome Rao et al133
140.  Simopoulos  AP.  Omega-3  fatty  acids  in
inflammation and autoimmune diseases. J Am Coll
Nutr 2002;21:495-505.
141. Gadek JE, DeMichele SJ, Karlstad MD, Pacht ER,
Donahoe M, Albertson TE, et al. Effect of enteral
feeding with eicosapentaenoic acid, gamma-
linolenic acid, and antioxidants in patients with
acute respiratory distress syndrome.  Enteral
Nutrition in ARDS Study Group. Crit Care Med
1999;27:1409-20.
142. Pacht ER, DeMichele SJ, Nelson JL, Hart J,
Wennberg AK, Gadek JE. Enteral nutrition with
eicosapentaenoic acid, gamma-linolenic acid, and
antioxidants  reduces alveolar  inflammatory
mediators and protein influx in patients with acute
respiratory distress syndrome. Crit Care Med
2003;31:491-500.
143. Singer P, Theilla  M, Fisher  H, Gibstein  L,
Grozovski E, Cohen J. Benefit of an enteral diet
enriched with eicosapentaenoic acid and gamma-
linolenic acid in ventilated patients with acute lung
injury. Crit Care Med 2006;34:1033-8.
144. Comparison of two fluid-management strategies
in acute  lung injury.  N Engl  J Med  2006;
354:2564-75.
145. Martin GS, Mangialardi RJ, Wheeler AP, Dupont
WD, Morris JA, Bernard GR. Albumin and
furosemide therapy in hypoproteinemic patients
with  acute  lung  injury.  Crit  Care  Med
2002;30:2175-82.
146. Connors AF Jr, Speroff T, Dawson NV, Thomas
C, Harrell FE Jr, Wagner D, et al. The effectiveness
of right heart catheterization in the initial care of
critically ill patients. SUPPORT Investigators.
JAMA 1996;276:889-97.
147. Harvey S, Harrison DA, Singer M, Ashcroft J,
Jones CM, Elbourne D, et al. Assessment of the
clinical effectiveness of pulmonary artery catheters
in management of patients in intensive care (PAC-
Man):  a randomised controlled trial.  Lancet
2005;366:472-7.
148. Rhodes A, Cusack RJ, Newman PJ, Grounds RM,
Bennett ED. A randomised, controlled trial of the
pulmonary artery catheter in critically ill patients.
Intensive Care Med 2002;28:256-64.
149. Rasanen J, Cane RD, Downs JB, Hurst JM, Jousela
IT, Kirby RR, et al. Airway pressure release
ventilation during acute lung injury: a prospective
multicenter trial. Crit Care Med 1991;19:1234-41.
150. Habashi NM. Other approaches to open-lung
ventilation: airway pressure release ventilation.
Crit Care Med 2005;33:S228-40.
151. Putensen C, Rasanen J, Lopez FA, Downs JB.
Effect  of  interfacing between  spontaneous
breathing and mechanical cycles on the ventilation-
perfusion  distribution in canine lung injury.
Anesthesiology 1994;81:921-30.
152. Putensen  C, Mutz NJ, Putensen-Himmer G,
Zinserling J.  Spontaneous breathing  during
ventilatory support improves ventilation-perfusion
distributions in patients with acute respiratory
distress syndrome. Am J Respir Crit care Med
1999;159:1241-8.
153.  Williams JG, Maier RV. Ketoconazole inhibits
alveolar macrophage production of inflammatory
mediators involved in acute lung injury (adult
respiratory  distress  syndrome).  Surgery
1992;112:270-7.
154. Slotman GJ, Burchard KW, D’Arezzo A, Gann DS.
Ketoconazole prevents acute respiratory failure in
critically  ill  surgical  patients.  J  Trauma
1988;28:648-54.
155. Yu M, Tomasa G. A double blind prospective
randomized trial of ketoconazole, a thromboxane
synthetase inhibitor, in the prophylaxis of adult
respiratory distress syndrome. Crit Care Med
1993;21:1635-42.
156. Sinuff T, Cook DJ, Peterson JC, Fuller  HD.
Development, implementation, and evaluation of
ketoconazole practice  guidelines for ARDS
prophylaxis. J Crit Care 1999;14:1-6.
157. Ketoconazole for early treatment of acute lung
injury and acute respiratory distress syndrome: a
randomized  controlled  trial.  JAMA
2000;283:1995-2002.
158. Bernard GR, Wheeler AP, Russell JA, Schein R,
Summer WR, Steinberg KP, et al.The effects of
ibuprofen on  the physiology and survival  of
patients with sepsis. The Ibuprofen in Sepsis Study
Group. N Engl J Med 1997;336:912-8.
159. Bulger EM, Maier RV. Lipid mediators in the
pathophysiology of critical illness. Crit Care Med
2000;28:N27-36.
160. Dandona P, Aljada A, Mohanty P, Ghanim H,
Hamouda W, Assian E, et al. Insulin inhibits
Acute respiratory distress syndrome Rao et al134
intranuclear factor {kappa} B and stimulates I
{kappa} B in mononuclear cells in obese subjects:
evidence for an anti-inflammatory effect? J Clin
Endocrinol Metab 2001;86:3257-65.
161. Van den Berghe G, Wouters P, Weekers F, Verwaest
C, Bruyninckx F, Schetz M, et al. Intensive insulin
therapy in critically Ill patients. N Engl J Med
2001;345:1359-67.
162. Van  den Berghe  G, Wilmer A, Hermans  G,
Meersseman W, Wouters PJ, Milants I, et al.
Intensive insulin therapy in medical ICU. N Engl
J Med 2006;354:449-61.
163.  Krinsley JS.  Effect of  an intensive  glucose
management protocolon the mortality of critically
ill adult patients. Mayo Clin Proc 2004;79:992-
1000.
164. Arabi YM,  Dabbagh OC,  Tamim HM, Al-
Shimemeri AA, Memish ZA, Haddad SH, et al.
Intensive versus conventional insulin therapy: a
randomized controlled trial in medical and surgical
critically  ill  patients.  Crit  Care  Med
2008;36:3190-7.
165. Weiner RE, Sasso DE, Gionfriddo MA, Thrall RS,
Syrbu S, Smilowitz HM, et al. Early detection of
oleic acid-induced lung injury in rats using (111)In-
labeled anti-rat intercellular adhesion molecule-
1. J Nucl Med 2001;42:1109-15.
166. Chen HI, Yeh DY, Liou H-L, Kao S-J. Insulin
attenuates endotoxin-induced acute lung injury in
conscious rats. Crit Care Med 2006;34:758-64.
167. Craig T, O’Kane CM, McAuley DF. Potential
mechanisms by which statins modulate pathogenic
mechanisms important in the development of acute
lung injury. In: Vincent JL, Ed. 27th yearbook of
intensive care and emergency medicine. Berlin,
Germany: Springer-Verlag 2007; pp. 287-300.
168. Frank JA, Parsons PE, Matthay MA. Pathogenetic
significance of biological markers of ventilator-
associated lung injury in experimental and clinical
studies. Chest 2006;130:1906-14.
169. Donnelly SC, Strieter RM, Kunkel SL, Walz A,
Robertson CR, Carter DC, et al. Interleukin-8 and
development  of  adult  respiratory  distress
syndrome  in at-risk  patient groups.  Lancet
1993;341:643-7.
170. Folkesson HG, Matthay MA, Hebert CA. Acid
aspiration-induced lung injury in rabbits is
mediated by interleukin-8 dependent mechanisms.
J clim Invest 1995;96:107-16.
171. Hopkins  RO, Weaver  LK, Collingridge  D,
Parkinson RB, Chan KJ, Orme JF Jr. Two-year
cognitive, emotional, and quality-of-life outcomes
in acute respiratory distress syndrome. Am J Respir
Crit Care Med 2005;171:340-7.
172. Valta P, Uusaro A, Nunes S, Ruokonen E, Takala
J. Acute respiratory distress syndrome: frequency,
clinical course, and costs of care. Crit Care Med
1999;27:2367-74.
173. Navarrete-Navarro P, Rodriguez A, Reynolds N,
West R,  Habashi N,  Rivera R,  et al. Acute
respiratory distress syndrome among trauma
patients: trends in ICU mortality, risk factors,
complications and resource utilization. Intensive
Care Med 2001;27:1133-40.
Acute respiratory distress syndrome Rao et al